Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A Broad-Spectrum Antiviral from the Ribonucleoside Analogue Class Is Starting Clinical Trials for Coronavirus

A Broad-Spectrum Antiviral from the Ribonucleoside Analogue Class Is Starting Clinical Trials for Coronavirus

As scientists seek a solution to the current coronavirus pandemic, researchers at the University of North Carolina are developing a new broad-spectrum antiviral drug against SARS-CoV-2, and clinical trials are expected to begin this spring. Earlier laboratory studies had found that the antiviral compound code-named EIDD-1931 reduced lung damage in animal models. Scientists are now continuing their work on using EIDD-2801, the orally available form of this compound, against SARS-CoV-2 infection.

A scientist involved in the study noted that three types of novel coronavirus had caused serious health problems over the past 20 years, adding: ‘There are many coronaviruses similar to SARS and MERS. They can recognize receptors such as ACE-2 on the surface of human respiratory tract cells and multiply rapidly in human lung cells. Taking all this into account, finding an effective antiviral drug is essential to resolve the current pandemic and prevent new outbreaks that we may encounter in the coming years.’

β-D-N4-hydroxytidine (NHC, EIDD-1931) is a broad-spectrum antiviral agent from the ribonucleoside analogue class, and its activity against RNA viruses (for example, influenza, Ebola, CoV and Venezuelan equine encephalitis virus) has been demonstrated in various laboratory studies.

The team reported positive results with NHC in laboratory experiments using human lung cells for SARS-CoV-2, MERS-CoV and SARS-CoV. They also noted that its orally available form, EIDD-2801, had been tested in mice. The study found that EIDD-2801 reduced lung damage and weight loss in mice infected with SARS-CoV or MERS-CoV. However, the lack of a suitable mouse model that fully mimics humans for SARS-CoV-2 is slowing the research. Science Translational Medicine published this study on April 6. Its lead author, Timothy Sheahan, stated: ‘We know that, in normal times, animal experiments are important for the future of a study. However, considering that these are not normal times and that we face a serious pandemic, this step can be skipped and testing in humans can begin’. Regarding another promising antiviral drug undergoing clinical trials for COVID-19 treatment, remdesivir, Maria Agostini, a PhD student at the Denison laboratory at Vanderbilt University, said: ‘Some viruses may have mechanisms of resistance to remdesivir and be more sensitive to EIDD-1931, and the reverse may also be observed. In this situation, using the two drugs together offers the possibility of effective treatment.’ Noting that, unlike remdesivir, the oral availability of EIDD-2801 is a major advantage, Sheahan concluded: ‘We have encountered 3 novel coronaviruses in the past 20 years; this shows that we will encounter similar situations with different coronaviruses in the future. EIDD-2801 has considerable potential for use not only against COVID-19 but also in outbreaks of new types of coronavirus that we may face in the future’.

Sources

1. Timothy P. Sheahan et al.
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Science Translational Medicine 06 Apr 2020.

2. Clinical Trial Evaluating Oral Drug against Coronavirus Expected to Start Later This Spring.
genengnews.com - 8 April 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A Broad-Spectrum Antiviral from the Ribonucleoside Analogue Class Is Starting Clinical Trials for Coronavirus

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy